Reuters logo
BRIEF-FDA approves Genentech's cancer immunotherapy Tecentriq
October 18, 2016 / 9:25 PM / a year ago

BRIEF-FDA approves Genentech's cancer immunotherapy Tecentriq

Oct 19 (Reuters) - Roche Holding AG :

* FDA approves Genentech’s cancer immunotherapy Tecentriq (atezolizumab) for people with a specific type of metastatic lung cancer

* Genentech- FDA approved Tecentriq for treatment of metastatic NSCLC who have disease progression during or following platinum-containing chemo Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below